Skip to main content
. Author manuscript; available in PMC: 2008 Jun 30.
Published in final edited form as: Clin Infect Dis. 2007 Aug 20;45(7):908–915. doi: 10.1086/521250

Table 1.

Patient and treatment characteristics for 269 individuals with 3170 person-months of follow-up.

Variable Patients with data Patients with missing data
Characteristic at baseline
 Nonwhite ethnicity 153 (58) 5 (2)
 Male sex 214 (80) 0
 Men who have sex with men 157 (58) 3 (1)
 Age, median years (IQR) 44 (38–49) 0
 Antiretroviral treatment
  PI 147 (55) 0
  NNRTI 95 (35) 0
  PI and NNRTI 20 (7) 0
  NRTI only 8 (3) 0
  Once daily 35 (13) 0
  Median no. of antiretroviral drugs in current regimen (IQR) 3 (3–4) 0
  Duration of current regimen, median months (IQR) 6 (3–13) 0
  Median no. of antiretroviral drugs experienced (IQR) 4 (3–6) 0
  Antiretroviral naive 107 (40) 0
  Mono- or dual-nucleoside exposure 113 (42) 0
Characteristic during follow-up
 Injection drug usea 83 (32) 7 (3)
 Crack usea 86 (33) 11 (4)
 Slept on street or in sheltera 49 (19) 11 (4)
 Intoxication in past month, mean no. of days (3SD)b 3.6 ± 7.6 c
 Nadir CD4+ cell count, median cells/μL (IQR) 168 (90–342)
 CD4+ cell count, median cells/μL (IQR)b 338 (195–532)
 Pillbox organizer use, person-months (%) 1371 (43) d
 Viral load ≤400 copies/mL, person-months (%) 1431 (45) e
 Viral load, median log10 copies/mL (IQR) 2.3 (1.0–4.1) e
 Pill count adherence,f median % (IQR) 86 (52–98) g

NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.

a

Reported in past 30 days at least once during follow-up.

b

Last value carried forward.

c

A total of 28 person-months (1% of total person-months of follow-up) lacked data.

d

A total of 12 person-months (0.4% of total person-months of follow-up) lacked data.

e

A total of 522 person-months (16% of total person-months of follow-up) lacked data.

f

Pill count adherence percentage was calculated as the difference between the current and previous pill counts divided by the prescribed number of doses for the same period.]

g

A total of 142 person-months (4% of total person-months of follow-up) lacked data.